GSK 14-Hour Requip CR “Approvable,” FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The company is “committed” to working with FDA to determine the best path forward.
You may also be interested in...
FDA Wants Solzira Restless Legs Data Reformatted
Filing’s content is unaffected, says GlaxoSmithKline, which withdrew the recently submitted NDA but will resubmit it “as quickly as possible.”
FDA Wants Solzira Restless Legs Data Reformatted
Filing’s content is unaffected, says GlaxoSmithKline, which withdrew the recently submitted NDA but will resubmit it “as quickly as possible.”
FDA Clears GSK’s Requip XL For Parkinson’s
Once-daily version is designed to battle generic competitors.